A. D. Toma

Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

G. Viscardi, G. Galli, M. Garassino, 2020 .

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy

A. Pedrocchi, Marcello Restelli, M. Boeri, 2022, Cancers.

184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

E. Zecca, G. Viscardi, G. Galli, 2021 .

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.

V. Torri, H. Wakelee, V. Pancaldi, 2020 .

Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.

D. Galetta, A. Addeo, G. Banna, 2020 .